Výsledky vyhledávání - "cdk 4/6 inhibitors"

Akademický článek

Expanded Indications of Molecular-Targeted Drugs in Perioperative Therapy of Breast Cancer

Autor: Eiichiro Noguchi, Sadako Akashi-Tanaka

Publikováno v: Tokyo Women's Medical University Journal, Vol advpub, Iss 0 (2024)

In recent years, numerous molecular-targeted drugs have become available for the perioperative therapy of breast cancer, bringing about a revolution in breast cancer treatment. Based on comprehensive gene expression analysis, breast cancer is classif

Externí odkaz: https://doaj.org/article/2f28d22739354c7b96296504c09bc865

Zobrazit plný text záznamu

Akademický článek

Oral SERDs alone or in combination with CDK 4/6 inhibitors in breast cancer: Current perspectives and clinical trials

Autor: Kleoniki Apostolidou, Eleni Zografos, Maria Alkistis Papatheodoridi, Oraianthi Fiste, Meletios Athanasios Dimopoulos, Flora Zagouri

Publikováno v: Breast, Vol 75, Iss , Pp 103729- (2024)

Over the past few decades, first-line therapy for treating advanced and metastatic HR+/HER2-breast cancer has transformed due to the introduction of adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitors (CDK 4/6i). However, there is

Externí odkaz: https://doaj.org/article/ce90e0cb4b9b49d7893e454d50307df2

Zobrazit plný text záznamu

Akademický článek

Do proton pump inhibitors affect the effectiveness of cyclin-dependent kinase 4/6 inhibitors in advanced HR positive, HER2 negative breast cancer? A meta-analysis

Autor: Francisco Cezar Aquino de Moraes, Caroline R. M. Pereira, Vitor Kendi Tsuchiya Sano, Estella Aparecida De Laia, Carlos Stecca, Rommel Mario Rodríguez Burbano

Publikováno v: Frontiers in Pharmacology, Vol 15 (2024)

Background:The CDK 4/6 inhibitors, including palbociclib and ribociclib, are the standard first-line treatment for hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. Proton pump inh

Externí odkaz: https://doaj.org/article/4df14e51740141ac89e067984942f7b2

Zobrazit plný text záznamu

Akademický článek

Exploring adherence in patients with advanced breast cancer: focus on CDK4/6 inhibitors

Autor: Baković Matea, Bago Martina, Benić Lucija, Krajinović Magdalena, Silovski Tajana, Plavetić Natalija Dedić, Turković Lu, Sertić Miranda, Hadžiabdić Maja Ortner

Publikováno v: Acta Pharmaceutica, Vol 73, Iss 4, Pp 633-654 (2023)

Treatment adherence is crucial for optimal outcomes in advanced breast cancer, but can be challenging due to various factors, i.e. patients’ attitudes and behavior upon diagnosis, and complex therapies with high adverse effect rates. Our aim was to

Externí odkaz: https://doaj.org/article/d0e30c0346e9458f8a1cd257fb165870

Zobrazit plný text záznamu

Akademický článek

Case report: Primary CDK4/6 inhibitor and endocrine therapy in locally advanced breast cancer and its effect on gut and intratumoral microbiota

Autor: Guilherme Vilhais, Diogo Alpuim Costa, Mário Fontes-Sousa, Pedro Casal Ribeiro, Filipa Martinho, Carolina Botelho de Sousa, Catarina Rodrigues Santos, Ida Negreiros, Ana Canastra, Paula Borralho, Ana Guia Pereira, Cristina Marçal, José Germano Sousa, Renata Chaleira, Júlio César Rocha, Conceição Calhau, Ana Faria

Publikováno v: Frontiers in Oncology, Vol 14 (2024)

Locally advanced breast cancer poses significant challenges to the multidisciplinary team, in particular with hormone receptor (HR) positive, HER2-negative tumors that classically yield lower pathological complete responses with chemotherapy. The inc

Externí odkaz: https://doaj.org/article/9d7afcb5d6a34ef7af322d501c24cad2

Zobrazit plný text záznamu

Akademický článek

Digging in real-word electronic database for assessing CDK 4/6 inhibitors adherence in breast cancer patients from Romania

Autor: Adina Turcu-Stiolica, Ion Udristoiu, Mihaela-Simona Subtirelu, Victor Gheorman, Madalina Aldea, Elena Adriana Dumitrescu, Simona Ruxandra Volovat, Dragos Mircea Median, Cristian Virgil Lungulescu

Publikováno v: Frontiers in Pharmacology, Vol 15 (2024)

Introduction: It is imperative for patients to respect the prescribed treatments to achieve the anticipated clinical outcomes, including the outpatients receiving oral anti-cancer drugs such as selective cyclin-dependent kinase 4/6 inhibitors (CDK 4/

Externí odkaz: https://doaj.org/article/c33395d3930f4fb2b6e62f7094b38576

Zobrazit plný text záznamu

Akademický článek

Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project

Autor: Marina Elena Cazzaniga, Antonio Ciaccio, Romano Danesi, Francois P. Duhoux, Corrado Girmenia, Kalhil Zaman, Henrik Lindman, Fabrizio Luppi, Dimitrios Mavroudis, Ida Paris, Ayodele Olubukola, Ahmed Samreen, Christian Schem, Christian Singer, Anton Snegovoy

Publikováno v: Frontiers in Oncology, Vol 13 (2023)

The personalization of therapies in breast cancer has favoured the introduction of new molecular-targeted therapies into clinical practice. Among them, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have acquired increasing importance, with the

Externí odkaz: https://doaj.org/article/b92d0fe6abaa453fb0590fe813591377

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání